ArticleBMC cancer2022

Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial).

Zhengyang Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.